ZNF613

Across TCGA pan-cancer cohorts, ZNF613 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ZNF613 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ZNF613 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF613 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

BLCA, KIRP, and BRCA are the cancer types where ZNF613 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.134	0.477	<.001	27	view →
KIRP	OS	Median	All	0.148	0.904	<.001	16	view →
BRCA	OS	Median	All	0.107	0.578	.013	12	view →
LUSC	OS	Median	II,III,IV	0.031	0.743	<.001	12	view →
LIHC	DFS	Median	III,IV	0.040	0.361	<.001	6	view →
UCEC	DFS	Median	All	0.956	0.626	.024	6	view →
LUAD	DFS	Median	All	1.000	0.325	.020	4	view →
COAD	OS	Median	All	0.168	0.805	.040	3	view →
SKCM	OS	Median	All	1.000	0.312	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ZNF613–BLCA (DFS)

Open the BLCA breakdown →